Notice of Proposed Sale · 144
Emergent Biosolutions, Inc.
EBSNYSEEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- EMERGENT BIOSOLUTIONS INC.
- Issuer CIK
- 0001367644
- SEC file number
- 001-33137
- Phone
- (240) 631-3200
- Person for whose account securities are to be sold
- PAUL WILLIAMS
- Relationships to issuer
- Officer
- Street
- 300 Professional Drive
- City
- Gaithersburg,
- State / country code
- MD
- Postal code
- 20879
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 3,000 | 19,591.50 | 51,273,336 | 10/01/2026 | NYSE | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 02/29/2024 | Restricted Stock | Issuer | 3,000 | N | 02/29/2024 | Not Applicable |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
The securities to be sold were acquired upon the vesting of restricted stock during the period of 02/29/2024 through 06/08/2025.
Notice signature
- Notice date
- 10/01/2026
- Signed
- /s/ Paul Anthony Williams
- Plan adoption dates
- 11/14/2025
Company context
Joseph Papa President and Chief Executive Officer Richard Lindahl EVP, Chief Financial Officer and Treasurer Jessica Perl SVP, General Counsel and Corporate Secretary Paul Williams SVP, Products Business Coleen Glessner EVP, Quality, Ethics and Compliance Simon Lowry, M.D. Chief Medical Officer, Head of Research and Development Stephanie Duatschek SVP, Chief Strategy and Transformation Officer Michelle Pepin SVP, Chief Human Resources Officer Bill Hartzel SVP, Manufacturing and Bioservices Emergent’s Executive Management Team
Current securities
Recent company filings
- Regulation FD DisclosureSep 14, 2026
- Other EventsSep 1, 2026
- 10-Q filingAug 6, 2026
- Results of Operations and Financial Condition · Costs Associated with Exit or Disposal Activities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureAug 5, 2026
- SCHEDULE 13G/A filingJul 31, 2026